ESSA Pharma Inc. (EPIX)
NASDAQ: EPIX · Real-Time Price · USD
1.600
0.00 (0.00%)
At close: Dec 20, 2024, 4:00 PM
1.610
+0.010 (0.63%)
After-hours: Dec 20, 2024, 5:54 PM EST
ESSA Pharma Employees
ESSA Pharma had 50 employees as of September 30, 2023. The number of employees did not change compared to the previous year.
Employees
50
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$570,856
Market Cap
71.02M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
P3 Health Partners | 400 |
908 Devices | 230 |
Vicarious Surgical | 131 |
Prelude Therapeutics | 128 |
Owlet | 76 |
Aerovate Therapeutics | 51 |
Werewolf Therapeutics | 47 |
Ovid Therapeutics | 40 |
EPIX News
- 4 days ago - ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024 - PRNewsWire
- 6 weeks ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ESSA Pharma Inc. (EPIX) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 6 weeks ago - ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 6 weeks ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Investors to Connect - Accesswire
- 6 weeks ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Stockholders to Connect - Accesswire
- 7 weeks ago - ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 7 weeks ago - ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer - PRNewsWire
- 3 months ago - ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress - PRNewsWire